Qsymia vs. Rybelsus
Qsymia and Rybelsus differ in their mechanisms and applications. Qsymia combines phentermine and topiramate for chronic weight management, while Rybelsus, an oral GLP-1 receptor agonist, is approved for type 2 diabetes management and provides moderate weight-loss benefits. Qsymia’s stimulant component may cause side effects like insomnia and mood changes, while Rybelsus is more commonly associated with nausea and gastrointestinal discomfort. Qsymia costs $300/month, while Rybelsus is priced at $875/month. Neither drug currently faces shortages.
Phentermine suppresses appetite by stimulating the release of norepinephrine in the brain; topiramate enhances feelings of fullness and alters taste perceptions, reducing food intake.
Common Side Effects
Dry mouth, insomnia, constipation, dizziness, and tingling in hands or feet.
Serious Potential Side Effects
Increased heart rate, mood changes, suicidal thoughts, and memory/concentration difficulties, dependency and abuse of medication
Slows gastric emptying, reduces appetite, and enhances feelings of fullness, leading to lower calorie intake. It also stimulates insulin release and reduces glucagon secretion, improving blood sugar control.
Common Side Effects
Nausea, diarrhea, vomiting, and abdominal pain.
Serious Potential Side Effects
Pancreatitis, thyroid tumors (potential risk), gallbladder issues, kidney problems, and serious allergic reactions